Gilde portfolio company Ablynx has raised EUR 75m in the largest biotech IPO on Euronext Brussels. The IPO was priced at EUR 7 per share. Pursuant to the offering, 10,714,285 new shares, equivalent to EUR 75m will be issued by Ablynx, and additionally, 1,607,142 over-allotment shares, equivalent to EUR11.25m will be allocated. If the over-allotment option is exercised in full, the total amount of the capital increase will amount to EUR 86.25m.
De Scorbiac was responsible for the Accenture Venture fund's activities in Europe
GP sells the Dutch employment agency to its CEO, ending its three-years ownership
Financing for the acquisition was provided by Santander Corporate and Commercial Banking
Sussex Place Ventures, Contour Ventures, Partnership Fund and Outrun Ventures also take part